背景:在医学专业中,医生与制药业之间存在普遍的财务关系,包括耳鼻喉科.尽管这些关系可能会导致利益冲突,没有研究评估日本耳鼻喉科医师和制药公司之间财务关系的规模和内容.这项研究旨在评估其大小,患病率,以及日本耳鼻喉科医生与制药公司之间财务关系的趋势。
方法:使用92家制药公司公开披露的支付数据,我们检查了尺寸,患病率,以及2016年至2019年间日本向日本耳鼻咽喉头颈外科学会(JSO-HNS)认证的耳鼻咽喉科医师委员会支付的个人付款趋势。此外,支付差异由耳鼻喉科医师是否是临床实践指南作者进行评估,协会董事会成员,和学术期刊编辑与否。通过广义估计方程评估了支付趋势。
结果:在8,190名耳鼻喉科医师中,3,667(44.8%)共支付了13,873,562美元,用于讲课,咨询,并在2016年至2019年期间由72家制药公司撰写。每位医生的四年综合付款中位数为$1,022(四分位数范围:$473-$2,526)。前1%,5%,10%的耳鼻喉科医师接受了42.3%(95%置信区间(95%CI):37.2%-47.4%),69.3%(95%CI:65.9%-72.8%),和总付款的80.6%(95%CI:78.3%-82.9%),分别。在撰写临床实践指南的耳鼻喉科医师中,每名医师的平均付款额显着较高($11,522),社会理事会成员(22,261美元),和期刊编辑(35143美元)比没有的人多。2016年至2019年期间,耳鼻喉科医生的付款和接受付款的人数保持稳定。
结论:这项研究表明,少数但大量耳鼻喉科医生收到了制药公司的个人报酬,用于报销讲课费用,咨询,在日本写作。这些个人付款中的大量主要集中在少数领先的耳鼻喉科医师身上。
BACKGROUND: There are prevalent financial relationships between physicians and the pharmaceutical industry in medical specialties, including otorhinolaryngology. Although these relationships might cause conflicts of interest, no studies have assessed the size and contents of the financial relationships between otorhinolaryngologists and pharmaceutical companies in Japan. This study aims to evaluate the magnitude, prevalence, and trend of the financial relationship between Japanese otolaryngologists and pharmaceutical companies.
METHODS: Using payment data publicly disclosed by 92 pharmaceutical companies, we examined the size, prevalence, and trend in personal payments made to the otorhinolaryngologist board certified by the Japanese Society of Otorhinolaryngology-Head and Neck Surgery (JSO-HNS) between 2016 and 2019 in Japan. Furthermore, differences in payments were evaluated by whether otolaryngologists were clinical practice guideline authors, society board members, and academic journal editors or not. Trends in payments were evaluated by generalized estimating equations.
RESULTS: Of 8,190 otorhinolaryngologists, 3,667 (44.8%) were paid a total of $13,873,562, in payments for lecturing, consulting, and writing by 72 pharmaceutical companies between 2016 and 2019. The median four-year combined payment per physician was $1,022 (interquartile range: $473-$2,526). Top 1%, 5%, and 10% of otorhinolaryngologists received 42.3% (95% confidence interval (95% CI): 37.2%-47.4%), 69.3% (95% CI: 65.9%-72.8%), and 80.6% (95% CI: 78.3%-82.9%) of overall payments, respectively. The median payments per physician were significantly higher among otorhinolaryngologists authoring clinical practice guidelines ($11,522), society board members ($22,261), and journal editors ($35,143) than those without. The payments and number of otorhinolaryngologists receiving payments remained stable between 2016 and 2019.
CONCLUSIONS: This study demonstrates that a minority but a large number of otorhinolaryngologists received personal payments from pharmaceutical companies for the reimbursement of lecturing, consulting, and writing in Japan. Large amounts of these personal payments were significantly concentrated on a small number of leading otorhinolaryngologists.